Výpis publikací

BUŠA, Daniel, Martin ČULEN, Tomáš LOJA, Ivana JEŽÍŠKOVÁ, Alois FOLTA a Jiří MAYER. Acute myeloid leukemia suppression by palbociclib and ponatinib in patient-derived xenograft. In 23. Pražské hematologické dny, Praha. 2023.

ČULEN, Martin, Daniel BUŠA, Zdeňka HERUDKOVÁ, Jan HÝL, Jakub VLAŽNÝ, Květoslava MATULOVÁ, Martin REPKO, Lucy VOJTOVÁ a Jiří MAYER. AML engraftment in humanized ossicles is not governed by biomaterial selection. In ESH: 4th Scientific Workshop: the Haematological Tumour Microenvironment and its Therapeutic Targeting, UK, Londýn. 2023.

ČULEN, Martin, Tomáš LOJA, Daniel BUŠA, Zdeňka HERUDKOVÁ, Jan HÝL, Jakub VLAŽNÝ, K. LIŠKOVÁ, Martin REPKO, Lucy VOJTOVÁ a Jiří MAYER. Biomaterial selection does not affect AML engraftment in humanized ossicles. In 12th International Conference Analytical Cytometry, Praha. 2023.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN a Michal ŠMÍDA. Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In 23. Pražské hematologické dny, Praha. 2023.

BUŠA, Daniel, Martin ČULEN, Tomáš LOJA, Ivana JEŽÍŠKOVÁ, Adam FOLTA a Jiří MAYER. Inhibition of acute myeloid leukemia using palbociclib and ponatinib in a patient-derived xenograft model. In Actual Problems of Medical Prevention, Baku, Azerbajdžán. 2023.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN a Michal ŠMÍDA. . Drug repurposing for venetoclax-resistant acute myeloid leukemia. In PhD retreat 2022, Telč. 2022.

BUŠA, Daniel, Martin ČULEN, Ivana JEŽÍŠKOVÁ, Adam FOLTA a Jiří MAYER. Acute myeloid leukemia suppression by palbociclib and ponatinib in patient-derived xenograft. In EHA 2022 in HemaSphere 2022; 6(S3): 574-575. 2022.

LODHI, Yusuf, Adriana LADUNGOVÁ, Daniel BUŠA, Helena PESCHELOVÁ, Martin ČULEN a Michal ŠMÍDA. Genome-wide Screening Optimizations and High-throughput Compound Screening to Identify Novel Treatment Options in Venetoclax-resistant AML. In Annual PhD conference Biomedical sciences, Brno. 2022.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN a Michal ŠMÍDA. Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In EHA 2022 in HemaSphere 2022; 6(S3): 626-627. 2022.

LADUNGOVÁ, Adriana, Daniel BUŠA, Helena PESCHELOVÁ, Yusuf LODHI, Martin ČULEN a Michal ŠMÍDA. Prediction of novel treatment options for CLL and AML cells based on drug repurposing. In CEITEC PhD Conference, Brno. 2022.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN a Michal ŠMÍDA. Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing. In Functional Precision Medicine for Blood Cancer Workshop and Symposium, Helsinki, Finland. 2022.

BUŠA, Daniel, Tomáš LOJA, Ivana JEŽÍŠKOVÁ, A. FOLTA, Jiří MAYER a Martin ČULEN. Acute myeloid leukemia regression induced by palbociclib and ponatinib in patient –derived xenograft model. In Analytická cytometrie XI. 2021.

BUŠA, Daniel, Tomáš LOJA, Ivana JEŽÍŠKOVÁ, Adam FOLTA, Jiří MAYER a Martin ČULEN. Palbociclib and ponatinib induce regression of acute myeloid leukemia in patient-derived xenograft model. In II. Český hematologický a transfuziologický sjezd v Transfuze a Hematologie Dnes (2021). 2021.